Tresiba Complete Drug-Drug Interaction Profile

How Tresiba Works: Mechanism Relevant to Drug Interactions

Insulin degludec lowers blood glucose by binding the insulin receptor, driving glucose uptake into skeletal muscle and adipose tissue, and suppressing hepatic glucose output. Its ultra-long action comes from a unique self-association mechanism: after subcutaneous injection, degludec molecules form soluble multi-hexameric chains that slowly dissociate into monomers at the depot site. [1]

This pharmacokinetic profile matters for interactions. Because the depot releases drug continuously over more than 42 hours, a co-administered agent that potentiates insulin action does not produce a sharp, time-limited effect. The hypoglycemia risk persists across the entire dosing interval.

Receptor-Level Pharmacology

Degludec binds the insulin receptor with affinity similar to human insulin. It has minimal IGF-1 receptor cross-reactivity (roughly 0.04% of insulin receptor affinity), which means growth-factor-mediated off-target effects are not a meaningful source of drug interactions. [2]

Protein Binding and Albumin

More than 99% of circulating degludec is albumin-bound. Drugs that displace albumin-bound ligands could theoretically increase free degludec concentration, though clinical data confirming this as a dominant mechanism are sparse. Highly protein-bound drugs such as salicylates at high doses are noted in the FDA label as potential hypoglycemia potentiators partly through this route. [3]

Hepatic and Renal Clearance

Degludec is degraded by insulin-degrading enzyme and protease activity in most tissues. It is not metabolized by CYP450 enzymes. [4] Renal impairment reduces insulin clearance and increases hypoglycemia susceptibility, making renally-cleared co-medications (for example, metformin, certain SGLT2 inhibitors) subject to additional scrutiny when renal function declines.

Drugs That Increase Hypoglycemia Risk

Pharmacodynamic interactions that amplify insulin's glucose-lowering effect represent the largest and most clinically dangerous category for Tresiba users.

Sulfonylureas and Meglitinides

Sulfonylureas (glipizide, glimepiride, glyburide) and meglitinides (repaglinide, nateglinide) stimulate pancreatic beta-cell insulin secretion independently of degludec's exogenous action. The combination produces additive and sometimes supra-additive hypoglycemia. The FDA label for degludec specifies that insulin secretagogues may require dose reduction when added to a basal insulin regimen. [3]

Glimepiride carries particular risk because its half-life extends to roughly 9 hours, overlapping substantially with each new degludec dose interval. A 2022 real-world analysis found combination insulin-plus-sulfonylurea therapy associated with a 2.2-fold increase in severe hypoglycemia events compared with insulin monotherapy. [5]

GLP-1 Receptor Agonists

GLP-1 agonists (semaglutide, liraglutide, dulaglutide, exenatide) lower postprandial glucose and, in some patients, fasting glucose substantially. When combined with degludec, they frequently allow a meaningful reduction in basal insulin dose. The DUAL I trial (N=1,030) demonstrated that combining degludec with liraglutide reduced HbA1c by 1.9 percentage points while requiring a 20% lower degludec dose than degludec alone. [6] Clinicians should preemptively reduce degludec by 10 to 20% when starting a GLP-1 agonist, with further titration guided by fasting glucose readings over the following 2 to 4 weeks.

Salicylates (High-Dose)

Aspirin at anti-inflammatory doses (greater than 2 grams per day) independently lowers blood glucose through several mechanisms: increased insulin secretion, inhibition of prostaglandin-E2-mediated beta-cell suppression, and possible albumin-displacement of bound degludec. [3] Analgesic doses (81 to 325 mg/day) carry negligible risk. Patients starting high-dose salicylate therapy for rheumatologic conditions should increase fasting glucose monitoring frequency to daily for at least 2 weeks.

Alcohol

Ethanol inhibits hepatic gluconeogenesis. In the presence of degludec, this effect removes the liver's primary compensatory mechanism during hypoglycemia, making recovery from low glucose both slower and shallower. [3] The risk is highest with drinking on an empty stomach after the degludec dose. Patients should be counseled to eat carbohydrates before or with alcohol consumption and to avoid drinking past the point of impaired judgment.

MAO Inhibitors

Monoamine oxidase inhibitors (phenelzine, tranylcypromine, selegiline at high doses) potentiate hypoglycemia through at least two pathways: suppression of epinephrine-mediated glycogenolysis and direct enhancement of peripheral glucose uptake. [3] The combination of a MAOI with any insulin is listed as requiring dose reduction in the FDA prescribing information. Because MAOIs are used infrequently, this interaction is often underestimated.

Pentamidine

Pentamidine, used for Pneumocystis jirovecii pneumonia, directly damages pancreatic beta cells. It causes an initial phase of hypoglycemia (from sudden insulin release out of damaged cells) followed, in some patients, by permanent hyperglycemia from beta-cell destruction. [7] Patients receiving IV or inhaled pentamidine alongside degludec need glucose monitoring every 4 to 6 hours during treatment.

Other Antidiabetic Agents

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) do not directly stimulate insulin secretion, but they reduce fasting glucose via glucosuria, and that additive effect can unmask relative insulin excess. The EMPA-REG and CANVAS programs both excluded patients already experiencing recurrent hypoglycemia, so the true combined hypoglycemia rate in fragile patients may be underestimated. [8] Dose reduction of degludec by 10 to 20% is a reasonable precaution when an SGLT2 inhibitor is added, especially in patients with eGFR <60 mL/min/1.73m².

Drugs That Decrease Insulin Efficacy

Some agents directly oppose degludec's glucose-lowering action, requiring upward dose adjustments to maintain glycemic targets.

Corticosteroids

Glucocorticoids (prednisone, dexamethasone, methylprednisolone) are among the most common causes of insulin resistance in hospitalized and outpatient settings. They increase hepatic glucose output, impair GLUT4 translocation in muscle, and stimulate glucagon secretion. Short-course prednisone 40 mg/day can increase insulin requirements by 30 to 50% in type 2 diabetes patients. [9]

The pattern of steroid-induced hyperglycemia is dose- and timing-dependent. Once-daily morning prednisone causes predominantly postprandial and afternoon hyperglycemia. Degludec's flat 42-hour profile does not match this pattern well. Clinicians may need to add a short-acting insulin at lunch and dinner rather than simply raising the degludec dose when patients are on morning glucocorticoids.

Thiazide and Loop Diuretics

Thiazide diuretics (hydrochlorothiazide, chlorthalidone) cause mild hyperglycemia through hypokalemia-mediated inhibition of pancreatic insulin secretion. The effect is dose-dependent and typically modest at low doses used in modern practice. Loop diuretics (furosemide, torsemide) carry a similar but smaller risk. [3] Routine monitoring of potassium alongside glucose is appropriate when adding or increasing diuretic therapy in a degludec user.

Atypical Antipsychotics

Olanzapine, clozapine, and quetiapine impair insulin sensitivity and stimulate appetite, increasing basal insulin requirements substantially. A 2019 meta-analysis found that olanzapine increased fasting glucose by a mean of 5.3 mg/dL more than risperidone in patients with comorbid diabetes. [10] Degludec dose adjustments of 20 to 40% may be needed within weeks of starting these agents.

Sympathomimetics

Epinephrine, pseudoephedrine, and other catecholamines stimulate glycogenolysis and gluconeogenesis. They also mask tachycardia (a warning sign of hypoglycemia). Albuterol at high nebulized doses can transiently raise glucose by 20 to 30 mg/dL. [3] This effect is usually clinically manageable in outpatients but becomes significant in ICU patients receiving dopamine or norepinephrine infusions alongside basal insulin.

Protease Inhibitors

HIV protease inhibitors (ritonavir, lopinavir, darunavir) cause insulin resistance and dyslipidemia as class effects. Patients starting antiretroviral therapy containing protease inhibitors should have fasting glucose reassessed at 4 and 12 weeks, with degludec titration guided by those results. [11]

Drugs With Mixed or Bidirectional Effects

A smaller group of agents can either raise or lower glucose depending on dose, duration, and patient context.

Beta-Blockers

Beta-blockers (metoprolol, atenolol, carvedilol, propranolol) interfere with insulin-degludec therapy in two distinct ways. First, non-selective agents (propranolol, carvedilol) block the beta-2-adrenergic-mediated symptoms of hypoglycemia (tremor, palpitations, anxiety), leaving sweating as the only reliable warning sign. Second, beta-blockers inhibit glycogenolysis, potentially deepening hypoglycemic episodes. [3]

Carvedilol is particularly complex because its alpha-1 blockade may actually improve insulin sensitivity, partially counteracting the hypoglycemia-masking concern. Beta-cardioselective agents (metoprolol, atenolol) are generally preferred in insulin-treated patients when beta-blockade is required.

Fluoroquinolone Antibiotics

Ciprofloxacin and levofloxacin have produced both severe hypoglycemia and hyperglycemia in post-marketing reports, particularly in elderly patients and those with renal impairment. [12] The FDA updated fluoroquinolone labeling in 2016 to include a warning about blood glucose disturbances. Patients on degludec starting a fluoroquinolone course should check glucose more frequently for the first 3 to 5 days.

Pharmacokinetic Interactions: CYP450 and Protein Binding

Because degludec is not metabolized by CYP450 enzymes, classic pharmacokinetic drug-drug interactions at the metabolic level are not applicable. [4] Agents that inhibit or induce CYP3A4, CYP2D6, or other major isozymes will not alter degludec plasma concentrations through those pathways.

The clinically relevant pharmacokinetic concerns are limited to:

• Injection-site interactions: concurrent use of hyaluronidase (Hylenex) accelerates insulin absorption from the depot, shortening time-to-peak and potentially altering the flat pharmacokinetic curve that characterizes degludec.
• Renal clearance effects: any nephrotoxic agent (contrast media, aminoglycosides, NSAIDs at high chronic doses) that reduces GFR will secondarily prolong degludec's effective duration by impairing insulin-degrading enzyme activity in tubular cells. [13]

The DEVOTE Trial: Real-World Interaction Context

The DEVOTE trial (N=7,637) randomized patients with type 2 diabetes at high cardiovascular risk to degludec or glargine U-100. Published in the New England Journal of Medicine in 2017, it found degludec non-inferior to glargine on major adverse cardiovascular events (MACE) and produced 53% fewer confirmed or severe nocturnal hypoglycemic episodes (rate ratio 0.47, 95% CI 0.38 to 0.58, P<0.001). [14]

From an interaction standpoint, DEVOTE is informative because the population heavily used cardiovascular co-medications (statins in 88% of participants, ACE inhibitors or ARBs in 75%). The lower nocturnal hypoglycemia rate with degludec persisted even in this polypharmacy-heavy cohort, suggesting degludec's flat pharmacokinetic profile provides some protection against the nighttime hypoglycemia that co-medications might otherwise worsen.

The American Diabetes Association 2024 Standards of Care state: "In patients at high risk for hypoglycemia, insulin degludec or glargine U-300 are preferred over NPH insulin or glargine U-100 based on lower hypoglycemia rates." [15]

Specific Population Considerations

Renal Impairment

The FDA label notes that insulin requirements may decrease in renal impairment, and this effect compounds any interaction with renally-cleared co-medications. Patients with eGFR <30 mL/min/1.73m² on degludec plus metformin should have metformin discontinued per standard guidance, and degludec doses should be reviewed at every visit given the changing pharmacokinetics of both agents as kidney function declines. [3]

Hepatic Impairment

Liver disease reduces gluconeogenesis capacity, making the hepatic compensation for hypoglycemia less effective. Patients with cirrhosis on degludec who are also receiving hepatically-metabolized drugs with glucose-altering properties (for example, propranolol for portal hypertension) need individualized monitoring plans rather than population-based dosing rules.

Pregnancy

Insulin requirements change throughout pregnancy. Progesterone and human placental lactogen both induce insulin resistance, typically increasing degludec requirements in the second and third trimesters. Co-medications used in obstetric care (betamethasone for fetal lung maturity, nifedipine for preterm labor) each carry their own glucose effects and require glucose monitoring intensification. [16]

Practical Interaction Management Framework

The following step-by-step framework applies to any new medication being added to a degludec regimen:

Step 1. Classify the interaction. Determine whether the new drug is a hypoglycemia potentiator, an insulin antagonist, or a bidirectional agent using the categories above.

Step 2. Quantify baseline control. Obtain a fasting glucose average from the preceding 2 weeks (or CGM time-in-range data if available). This is the reference point for detecting any change caused by the interaction.

Step 3. Apply the pre-emptive dose adjustment. For potentiators, reduce degludec by 10 to 20% before the first dose of the new drug. For antagonists, plan to increase degludec by 10 to 20% starting day 3 to 7 of the new medication.

Step 4. Set a monitoring window. For high-risk interactions (sulfonylureas, MAOIs, pentamidine, corticosteroids), check fasting glucose daily for 14 days and at 30 days. For lower-risk interactions (thiazides, beta-blockers, atypical antipsychotics), weekly fasting glucose for 4 weeks is usually adequate.

Step 5. Document and communicate. Every dose change triggered by a drug interaction should be recorded with the triggering medication, the date, and the target glucose range so any subsequent provider can reconstruct the rationale.

Drug Interaction Summary Table

| Drug or Class | Interaction Direction | Mechanism | Monitoring Recommendation | |---|---|---|---| | Sulfonylureas / meglitinides | Potentiates hypoglycemia | Additive secretagogue effect | Daily fasting glucose x 14 days; consider 10-20% degludec reduction | | GLP-1 receptor agonists | Potentiates hypoglycemia | Additive glucose-lowering | Reduce degludec 10-20% at initiation; titrate by fasting glucose | | High-dose salicylates | Potentiates hypoglycemia | Beta-cell stimulation, albumin displacement | Daily glucose x 2 weeks | | Alcohol | Potentiates hypoglycemia | Inhibits hepatic gluconeogenesis | Counsel on carbohydrate intake; avoid fasting drinking | | MAO inhibitors | Potentiates hypoglycemia | Suppresses epinephrine-driven glycogenolysis | Dose reduction required; daily glucose monitoring | | Pentamidine | Potentiates then antagonizes | Beta-cell toxicity (biphasic) | Glucose q4-6h during therapy | | Corticosteroids | Antagonizes insulin | Insulin resistance, increased hepatic output | Increase degludec 20-50%; may need prandial insulin | | Thiazide / loop diuretics | Antagonizes insulin (mild) | Hypokalemia-mediated beta-cell suppression | Monitor potassium and glucose; titrate if needed | | Atypical antipsychotics | Antagonizes insulin | Impaired insulin sensitivity, weight gain | Reassess degludec dose at 4 and 12 weeks | | Protease inhibitors | Antagonizes insulin | Class-effect insulin resistance | Fasting glucose at 4 and 12 weeks after ART initiation | | Beta-blockers | Mixed / masks symptoms | Blunts adrenergic hypoglycemia signs | Prefer cardioselective agents; reinforce sweating as warning | | Fluoroquinolones | Mixed / unpredictable | Unknown, post-marketing reports | Increase self-monitoring for first 3-5 days of course | | SGLT2 inhibitors | Mild potentiation | Additive glycosuria-driven glucose lowering | Consider 10-20% degludec reduction in susceptible patients | | Sympathomimetics | Antagonizes insulin | Stimulates glycogenolysis and gluconeogenesis | Transient; monitor glucose; usually self-limited | | Hyaluronidase (Hylenex) | Alters pharmacokinetics | Accelerates depot absorption | Adjust injection timing; monitor for earlier hypoglycemia |